IE63467B1 - Use of adamantane derivatives for the prevention and treatment of cerebral ischaemia - Google Patents

Use of adamantane derivatives for the prevention and treatment of cerebral ischaemia

Info

Publication number
IE63467B1
IE63467B1 IE99690A IE99690A IE63467B1 IE 63467 B1 IE63467 B1 IE 63467B1 IE 99690 A IE99690 A IE 99690A IE 99690 A IE99690 A IE 99690A IE 63467 B1 IE63467 B1 IE 63467B1
Authority
IE
Ireland
Prior art keywords
adamantane
amino
ethyl
hydrogen
use according
Prior art date
Application number
IE99690A
Other languages
English (en)
Other versions
IE900996L (en
Inventor
Joachim Bormann
Markus R Gold
Wolfgang Schatton
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8201228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IE63467(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Publication of IE900996L publication Critical patent/IE900996L/en
Publication of IE63467B1 publication Critical patent/IE63467B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IE99690A 1989-04-14 1990-03-16 Use of adamantane derivatives for the prevention and treatment of cerebral ischaemia IE63467B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP89106657A EP0392059B1 (de) 1989-04-14 1989-04-14 Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie

Publications (2)

Publication Number Publication Date
IE900996L IE900996L (en) 1990-10-14
IE63467B1 true IE63467B1 (en) 1995-04-19

Family

ID=8201228

Family Applications (1)

Application Number Title Priority Date Filing Date
IE99690A IE63467B1 (en) 1989-04-14 1990-03-16 Use of adamantane derivatives for the prevention and treatment of cerebral ischaemia

Country Status (16)

Country Link
US (1) US5061703A (enExample)
EP (1) EP0392059B1 (enExample)
JP (1) JP2821233B2 (enExample)
AT (1) ATE94384T1 (enExample)
CA (1) CA2014453C (enExample)
CH (1) CH679208A5 (enExample)
DD (1) DD293493A5 (enExample)
DE (2) DE58905637D1 (enExample)
DK (1) DK173356B1 (enExample)
ES (1) ES2059602T3 (enExample)
HU (1) HU215592B (enExample)
IE (1) IE63467B1 (enExample)
LU (1) LU90988I2 (enExample)
NL (1) NL300107I1 (enExample)
PT (1) PT93763B (enExample)
SE (1) SE9001329L (enExample)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
DE19510189A1 (de) * 1995-03-21 1996-09-26 Hartmut Dr Goebel Verwendung von Amantadin
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
GB9802225D0 (en) 1998-02-02 1998-04-01 Cerebrus Ltd Chemical compounds
RU2147573C1 (ru) * 1998-08-24 2000-04-20 Волгоградский государственный технический университет Способ получения адамант-1-иламина и его производных
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
US20040248984A1 (en) * 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
AU2002333510A1 (en) 2001-08-29 2003-03-18 Eucro European Contract Research Gmbh And Co. Kg Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
GB0202161D0 (en) * 2002-01-30 2002-03-20 Vernalis Res Ltd Chemical compounds V
WO2004009062A2 (en) * 2002-07-19 2004-01-29 Khalid Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
TW200418446A (en) 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RU2246482C2 (ru) * 2002-12-25 2005-02-20 ООО "Циклан" Способ получения гидрохлорида 1-амино-3,5-диметиладамантана
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
CN100345819C (zh) * 2003-07-01 2007-10-31 北京德众万全药物技术开发有限公司 一种取代的金刚烷胺类化合物或其盐的制备方法
ITTO20030668A1 (it) * 2003-09-02 2005-03-03 Rotta Res Lab S P A O Ra Rottapharm Derivati dell'adamantano dotati di attivita' neuroprotettiva, antidepressiva e anti-ischemica e procedimento per la loro preparazione.
CN1240668C (zh) * 2003-09-10 2006-02-08 上海医药工业研究院 一种新的盐酸美金刚制备方法
WO2005079779A1 (en) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP5025468B2 (ja) * 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
TW200621677A (en) * 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
WO2006034465A1 (en) * 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
CN100351225C (zh) * 2004-10-28 2007-11-28 中国医学科学院医药生物技术研究所 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
WO2006076562A1 (en) * 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
ITMI20050833A1 (it) 2005-05-10 2006-11-11 A M S A S P A Anonima Materie Sintetiche Affini Nuovo procedimento per la sintesi di aminoadamantani
EP1879849A1 (en) * 2005-05-11 2008-01-23 Dr. Reddy's Laboratories, Inc. Process for preparing memantine
EP1898890A1 (en) * 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
ES2528451T3 (es) 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
RU2309940C2 (ru) * 2005-09-30 2007-11-10 НПЦ "Фармзащита" Способ получения 3,5-диметиладамантил-1-амина или его солей
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
ATE541827T1 (de) 2006-02-21 2012-02-15 Hexal Ag Verfahren zur herstellung von adamantanaminen
DE102006009279A1 (de) * 2006-03-01 2007-09-06 Justus-Liebig-Universität Giessen Verfahren zur Herstellung von 1-Formamido-3,5-dimethyladamantan
DE102006009278B4 (de) * 2006-03-01 2010-06-02 Justus-Liebig-Universität Giessen Verfahren zur direkten Formamidierung oder Acetamidierung von Admantan und Admantanderivaten sowie deren Verwendung zur Herstellung von Aminoadmantanen
EP1999100A1 (en) 2006-03-27 2008-12-10 Teva Pharmaceutical Fine Chemicals S.R.L. Process for preparing memantine hydrochloride substantially free of impurities
WO2008002594A2 (en) * 2006-06-27 2008-01-03 Neuroprotection For Life Corp. Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
ES2412384T3 (es) * 2006-07-18 2013-07-11 Astellas Pharma Inc. Derivado de aminoindano o sal del mismo
MX2009001036A (es) 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
WO2008062472A2 (en) * 2006-10-24 2008-05-29 Cadila Healthcare Limited Process for the preparation of memantine
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
US8648059B2 (en) * 2008-03-13 2014-02-11 The Regents Of The University Of California Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling
EP2103597A1 (en) 2008-03-20 2009-09-23 Merz Pharma GmbH & Co.KGaA Process for the manufacture of memantine and intermediate product
ES2507085T3 (es) * 2008-03-20 2014-10-14 Merz Pharma Gmbh & Co. Kgaa Proceso para la fabricación de Memantina y producto intermedio
KR100998525B1 (ko) 2008-03-28 2010-12-07 나노다이아몬드 주식회사 아밀로이드 올리고머 독성 억제제로서의 아다만탄 유도체
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
WO2011015265A2 (en) 2009-08-04 2011-02-10 Merck Patent Gmbh Electronic devices comprising multi cyclic hydrocarbons
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
PL2578212T3 (pl) 2010-05-24 2017-01-31 Farmalider Sa Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
AR083475A1 (es) 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
MX2013004760A (es) 2010-10-29 2013-07-02 Merz Pharma Gmbh & Co Kgaa Derivados de indol y proceso para su preparacion.
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
AR084516A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
US20140004189A1 (en) 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
WO2012152854A1 (en) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
EP2650284A1 (en) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
KR20140146192A (ko) 2012-04-14 2014-12-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3102186B1 (en) 2014-02-04 2021-01-27 Forest Laboratories Holdings Limited Donepezil compositions and method of treating alzheimer's disease
IL234638A0 (en) 2014-09-14 2014-12-02 Yeda Res & Dev NMDA receptor antagonists for the treatment of Gaucher disease
MX392119B (es) 2015-06-19 2025-03-11 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US10583171B2 (en) 2015-11-30 2020-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale) NMDAR antagonists for the treatment of diseases associated with angiogenesis
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
CA3011538A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamantane derivatives for the treatment of filovirus infection
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
EP3490544A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Memantine transdermal delivery systems
WO2018022814A1 (en) 2016-07-27 2018-02-01 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
CN116270551A (zh) 2016-07-27 2023-06-23 考里安有限责任公司 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
EP3890714A4 (en) 2018-12-05 2022-02-23 Regents of the University of California ANTI-CANCER ACTIVITY OF ADAMANTAN DERIVATIVES
BR112021024054A2 (pt) 2019-05-31 2022-01-11 Tecnimede Sociedade Tecnico Medicinal Sa Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos.
EP4005565A1 (en) 2020-11-30 2022-06-01 Merz Pharmaceuticals GmbH Novel uses of adamantane derivatives
CN119095622A (zh) 2022-02-08 2024-12-06 菲克雷特·萨欣 Nmdar拮抗剂通过提高20s蛋白酶体活性来预防老化和老化相关病况和疾病
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450761A (en) * 1967-03-30 1969-06-17 Sun Oil Co 1-aminoethyldimethyladamantane
US4748154A (en) * 1985-12-24 1988-05-31 Takeda Chemical Industries, Ltd. Peptide derivatives, their production and use
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer

Also Published As

Publication number Publication date
SE9001329D0 (sv) 1990-04-11
US5061703A (en) 1991-10-29
CH679208A5 (enExample) 1992-01-15
IE900996L (en) 1990-10-14
JPH02292214A (ja) 1990-12-03
CA2014453C (en) 2000-03-28
DE10299048I1 (de) 2003-03-27
DK91690D0 (da) 1990-04-11
PT93763B (pt) 1996-04-30
EP0392059A1 (de) 1990-10-17
HU902434D0 (en) 1990-08-28
DE10299048I2 (de) 2006-07-13
SE9001329L (sv) 1990-10-15
ATE94384T1 (de) 1993-10-15
HUT58200A (en) 1992-02-28
DK91690A (da) 1990-10-15
DE58905637D1 (de) 1993-10-21
DK173356B1 (da) 2000-08-07
LU90988I2 (fr) 2003-01-13
PT93763A (pt) 1990-11-20
JP2821233B2 (ja) 1998-11-05
EP0392059B1 (de) 1993-09-15
CA2014453A1 (en) 1990-10-14
NL300107I2 (nl) 2003-02-03
NL300107I1 (nl) 2003-02-03
HU215592B (hu) 1999-01-28
DD293493A5 (de) 1991-09-05
ES2059602T3 (es) 1994-11-16

Similar Documents

Publication Publication Date Title
IE63467B1 (en) Use of adamantane derivatives for the prevention and treatment of cerebral ischaemia
HU226110B1 (en) 1-amino-alkylcyclohexane nmda receptor antagonists, pharmaceutical compositions containing and their use
LT4455B (lt) N-propargil-1-aminoindano r-entantiomero, jo druskų ir jo kompozicijų panaudojimas
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
JP2003523989A (ja) 治療剤としてのアミノアダマンタン誘導体
JPH06509335A (ja) アシルメルカプトアルカノイルジペプチド類、その製造方法及びその治療学的使用
JP2003521470A (ja) ベンラファキシンの誘導体とその調製および使用方法
EP1749522A2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
EP0284621A1 (en) PSYCHOSTIMULATING AGENT.
KR100581451B1 (ko) 1,7,7-트리메틸-바이시클로[2.2.1]헵탄 유도체
CN111285923B (zh) 一种psd-95抑制剂
US3341593A (en) 1-p-hydroxyphenyl-2-(beta-3', 5'-dihydroxyphenyl-beta-hydroxy)-ethylamino-propanes
EP0694299B1 (en) The use of( a) bicycloheptane derivative(s)
CN107753469B (zh) Ndga类似物在制备抗氧化药物中的应用
US6498196B1 (en) Compounds useful in pain management
AU2007286651A1 (en) 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
US5652270A (en) Pharmaceutical compositions containing bicycloheptane ether amines and a process for the preparation thereof
CN101712658A (zh) 1-丁基-2-羟基芳烷哌嗪衍生物及作为抗抑郁剂应用
EP1848426B1 (en) Tricyclic cytoprotective compounds
US5955493A (en) Thiamorphinans with neuroprotective activity
US3789070A (en) Prophylaxis and treatment of cardiac 3,4,5-trialkoxyphenylalkanoic acids and salts thereof
US6083992A (en) Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial infections
CA3210043A1 (en) Therapeutic compounds and methods of use thereof
KR830001683B1 (ko) 4급 암모늄 부정맥 치료제의 제조방법
EP2093218A1 (en) Arylalkyl substituted imidazolidinones

Legal Events

Date Code Title Description
SPCF Request for grant of supplementary protection certificate

Free format text: SPC030/2002: 20021106, EXPIRES: 20100316

Spc suppl protection certif: SPC030/2002

Filing date: 20021106

Expiry date: 20100316

SPCG Supplementary protection certificate granted

Free format text: SPC030/2002: 20040930, EXPIRES: 20150315

Spc suppl protection certif: SPC030/2002

Filing date: 20040930

Expiry date: 20150315

MK9A Patent expired
SPCI Supplementary protection certificate declared invalid

Free format text: PRODUCT NAME: MEMANTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/219/001-006 20020515

Spc suppl protection certif: 2002/030

Filing date: 20021106

Effective date: 20120228